» Articles » PMID: 39711024

Group A Streptococcal Infections in Alberta, Canada 2018-2023

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Group A streptococcal or infections have been increasing post-COVID-19 pandemic. We describe the epidemiology of pharyngitis and invasive disease in Alberta, Canada 2018-2023. Positive pharyngitis specimens were identified from throat swabs collected from pharyngitis patients. Invasive was defined as the isolation of from a normally sterile site or severe skin infection. isolates were typed. Pharyngitis and invasive disease displayed seasonal trends preceding the COVID-19 pandemic followed by a sharp decrease during COVID-19 intervention measures. After the lifting of interventions, rates of pharyngitis and invasive disease rose. There were 182 983 positive pharyngitis specimens between 2018 and 2023 for a positivity rate of 17.6%. The highest rates occurred in the 0-9 age group in 2023 (41.5%). Invasive disease increased in 2022-2023 driven by 1 and 12 types. M1 strain was the most frequent M1 type associated with invasive disease (59% of M1 isolates sequenced). Notably, out of 182 983 pharyngitis cases, there were 111 cases of invasive detected for an invasive disease rate of 0.06%. This descriptive epidemiology of pharyngitis and invasive disease highlights the rapid increase in cases of occurring in western Canada and illustrates the critical need for a vaccine.

References
1.
Fischetti V . Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev. 1989; 2(3):285-314. PMC: 358122. DOI: 10.1128/CMR.2.3.285. View

2.
Li Y, Rivers J, Mathis S, Li Z, McGee L, Chochua S . Continued Increase of Erythromycin Nonsusceptibility and Clindamycin Nonsusceptibility Among Invasive Group A Streptococci Driven by Genomic Clusters, United States, 2018-2019. Clin Infect Dis. 2022; 76(3):e1266-e1269. PMC: 11120049. DOI: 10.1093/cid/ciac468. View

3.
Kennis M, Tagawa A, Kung V, Montalbano G, Narvaez I, Franco-Paredes C . Seasonal variations and risk factors of infection: a multicenter research network study. Ther Adv Infect Dis. 2022; 9:20499361221132101. PMC: 9585558. DOI: 10.1177/20499361221132101. View

4.
Li H, Zhi X, Vieira A, Whitwell H, Schricker A, Jauneikaite E . Characterization of emergent toxigenic M1 and associated sublineages. Microb Genom. 2023; 9(4). PMC: 10210942. DOI: 10.1099/mgen.0.000994. View

5.
Powell L, Choi S, Haught B, Demkowicz R, LaSala P, Lukomski S . Prevalence of erythromycin-resistant emm92-type invasive group A streptococcal infections among injection drug users in West Virginia, United States, 2021-23. J Antimicrob Chemother. 2023; 78(10):2554-2558. DOI: 10.1093/jac/dkad268. View